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In a previous commentary we have discussed some potential sources of heterogeneity of the 
antidepressant effects of exercise in people with depression, and provided suggestions on how 
to explore them in order to promote a broader understanding of the topic. These sources of 
heterogeneity  were discussed focussing on the PICOS criteria referred to participants, 
interventions, comparisons, outcomes, and study designs. In response, Drs. Legrand and Neffs 
raised the discussion on 1) whether different symptomatology is able to moderate the 
antidepressant effects of exercise; 2) what is the "optimal dose" of exercise, which includes 
discussion on how to identify it, how to identify its biological correlates and how to shape 
exercise interventions, and  3) the necessity and validity of pragmatic RCTs. In the present 
manuscript, we have clarified and further expanded the points raised by Drs. Legrand and Neff. 
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We would like to thank Drs Legrand and Neff for their interest in our paper, in which we 
discussed how the scientific community could advance further to understand the 
antidepressant role of exercise for individuals with depression, investigating potential sources 
of heterogeneities on the outcomes (1). Drs Legrand and Neff raised several interesting points 
and we are grateful for the opportunity to respond (2). Their points related to our suggestions 
that (a) different subtypes of depression (and other biological, clinical, psychological, social 
characteristics) may moderate the antidepressant effects of exercise; (b) designing exercise 
interventions should take into account the putative biological mediators involved; and (c) more 
pragmatic randomized controlled trials (RCTs) are needed due their "high external validity 
(outcome generalizability) by virtue of methodological features that are more closely aligned 
with ‘real life’ practice norms." Here, we wish to clarify and briefly expand on these points. 
First, we suggested that, since depression exhibits heterogeneous symptomatology and 
biopsychosocial correlates, it is reasonable to assume that this heterogeneity will likely 
influence the effects of exercise on individuals with depression. Drs Legrand and Neff argued 
that the source we cited to support this point "is presented as a review article about the 
'moderators of response in exercise treatment or depression,' but it actually included a very 
small number of studies (n = 11), and some of the presented conclusions have been drawn on 
the basis of one single study." We would like to clarify that our point primarily reflected a 
theoretical postulate, namely that "patients with similar scores on measures of depression may 
experience dissimilar symptoms... This heterogeneity in symptoms may reﬂect differences in 
underlying neurobiological processes..., suggesting that the same exercise prescription may be 
less effective for some patients and more effective for others" (p. 2)(3). Related to this 
postulate, we cited a review as providing "initial evidence" suggesting that "clinical (severity of 
somatic symptoms), biological [brain derived neurotrophic factor, (BDNF) and tumor necrosis 
factor-α], psychological (self-esteem and life satisfaction), and social factors (support and 
marital status) may moderate the antidepressant effects of exercise" (p. 2). We thus concur 
that conclusive evidence supporting our point is still lacking. In fact, we stated that, in the 
future, researchers can "conduct moderator analyses to identify depressed subgroups with 
symptomatology and biopsychosocial characteristics associated with differential responses to 
exercise interventions," in order to test this assumption. Interestingly, since the publication of 
our initial paper, a study by Rethrost et al. (4) identified that patients with atypical depression 
are more likely to respond to exercise compared to patients with melancholic depression. 
Clearly, more research on this issue is needed. 
Secondly, Drs Legrand and Neff raised three points pertaining to our discussion of the 
challenges involved in identifying the "optimal dose" of exercise. a) Their first point was that 
"the majority of trials that used exercise (aerobic or anaerobic) in the management of clinical 
depression did not quantify physical activity in terms of energy expenditure (expressed in 
kilocalories/week) but rather in terms of time spent at various relative intensities." While it is 
true that most reports specify the prescribed dose of exercise in terms of intensity and 
duration (e.g., percentage of maximal aerobic capacity for intensity and number of minutes 
per session for duration), this approach is essentially interchangeable with describing exercise 
prescriptions in terms of energy expenditure (e.g., kcal per week), once body mass is taken 
into account (see p. 176 of the ACSM Guidelines for Exercise Testing and Prescription, 9th 
edition(5)). b) The second point made by Drs Legrand and Neff was that they do not "think that 
any method employed in quantifying the prescribed 'dose' of physical activity will help in 
identifying the biological mechanisms through which exercise decreases depression." We 
should clarify that we did not state that using a certain dose of exercise could provide 
information regarding the potential biological mechanisms. Our point was that the exercise 
prescription should be designed to take advantage of the postulated mechanisms underlying 
the antidepressant effect. For example, to promote the upregulation of Brain-Derived 
Neurotrophic Factor (BDNF), as one of the biological mechanisms accounting for the 
antidepressant effects of exercise (6), researchers should consider the evidence on the types 
and doses of exercise that optimize this effect. Specifically, optimizing BDNF upregulation 
seems to require low-intensity exercise (7). Furthermore, voluntary, self-paced exercise 
appears to be more effective than imposed exercise (8) and may prolong the elevation of 
BDNF (9). Moreover, in humans, the endocannabinoid anandamide in plasma has been found 
to be correlated with BDNF (10). Since anandamide is closely related to affective responses to 
exercise (11), these findings suggest that, to upregulate BDNF and stimulate neuroplasticity, an 
exercise stimulus may be required that (perhaps above all else) is experienced as pleasant. 
Thus, it should be apparent that an exercise prescription designed to optimize the 
antidepressant effect may be substantially different from a typical prescription, the purpose of 
which has traditionally been the promotion of adaptations in the cardiovascular system. c) The 
third point raised by Drs Legrand and Neff was that "it is doubtful that an exercise prescription 
can be shaped to target a specific 'putative mechanism of the antidepressant effects of 
exercise'." In support of this argument, they cited the study by Schmolesky et al. (2013)(12), 
which found no difference between "moderate" (60% heart rate reserve) or "vigorous" (80% 
heart rate reserve) and "short" (20 minutes) or "long" (40 minutes) exercise conditions in 
serum levels of BDNF in healthy men. However, Schmolesky et al. acknowledged that the 
increase in BDNF was highest in their lowest-intensity and shortest-duration group, albeit the 
difference was not statistically significant due to the low level of statistical power (see p. 507, 
also see their Figure 1C). Moreover, it should be noted that both intensities employed in the 
study by Schmolesky et al. (i.e., 60% and 80% of heart rate reserve) are considered 
"hard/vigorous" by the American College of Sports Medicine (this range is defined as 60-84% 
of oxygen uptake or heart rate reserve, or 77-93% of maximal heart rate)(5). 
The fourth point by Drs Legrand and Neff was related to our proposal for more pragmatic RCTs 
that replicate routine practice conditions. Instead, Drs Legrand and Neff argued that "what 
seems mostly needed is to develop RCTs conducted with a high degree of internal validity." 
First, although internal and external validity are usually reciprocally related, it is erroneous to 
think of them as necessarily antithetical, fundamentally incompatible, or mutually exclusive. 
Instead, the challenge is to maintain balance between the two (13). Also, exercise has shown 
established antidepressant efficacy under optimal-(clinical) conditions (i.e., with select and 
highly motivated participants, expertly administered treatments, etc) because both large 
clinical RCTs and meta-analyses have repeatedly provided relevant clinical evidence (14). What 
is currently set into question, in our view, is the antidepressant effectiveness of exercise in 
routine practice given the lack of pragmatic RCTs (15). Thus, the next step is to explore how 
clinical evidence can be translated into a pragmatic rationale for routine practice. In particular, 
how exercise guidelines for depression-3 times/per week for a period of 12 to 14 weeks - (13) 
can be efficiently conducted under or adapted (and updated) to non-optimal conditions, 
specifically, pragmatic conditions that routine practice is daily faced with. These conditions 
include diverse and referred-instead of homogenous and exclusively voluntary-samples, 
increased difficulties in compliance due to psychosocial and environmental barriers commonly 
seen in daily life, non-expertly administered treatments, and untailored or incompatible 
exercise facilities and involved milieu to the needs of depressed people.  
In this vein, RCTs with pragmatic design can make a real difference in people living with 
depression, especially since they measure effectiveness which is defined as “the benefit the 
treatment produces in routine practice” (16). To this extent, pragmatic RCTs are based on 
externally valid methodological criteria; recruitment of heterogeneous samples via patients’ 
presentation and wide inclusion criteria, assessment on functional outcomes (17), acceptance 
of non-blinded therapists/patients (18), and suitability to compare usual to new treatments 
(19). Hence, pragmatic trials provide routine practice with direct evidence attributable to 
increased external validity. This is of major importance as the treatment of depression is 
realised mainly in primary care.  
To the best of our knowledge, there has been only one pragmatic exercise RCT for people with 
depression (20). Trialists found a statistically significant large antidepressant effect-size (ES) for 
preferred intensity exercise vs. prescribed intensity exercise implemented three times per 
week for a period of four weeks. This finding becomes more important in light of the facts 
that: i) exercise guidelines for depression recommend 12-14 weeks of exercising (13), and ii) 
pragmatic RCTs tend to reveal small ESs for the intervention (21) attributable, among other 
reasons, to the large standard deviation of the primary outcome of interest (e.g., depression) 
resulting from the lack of exclusion criteria in terms of severity (e.g., cut off point).  
Drs Legrand and Neff have also raised a fifth point, underling that outcomes of pragmatic RCTs 
are not confound free. Indeed, pragmatic RCTS present increased risk of bias caused by 
confounding variables when comparable to trials conducted in a more homogeneous scenario. 
This risk, however, could be decreased when pragmatic RCTs are theory-driven and some of 
the previously identified confound factors are evaluated or controlled. For example, in the 
pragmatic RCT by Callaghan et al (2011)(20), both the intervention and the control groups 
received social support enforcement and, moreover, both groups showed comparable 
improvement in levels of social support at discharge. Thus, social support cannot be 
necessarily seen as a confounding factor in this trial.  
Building the bridge between clinical evidence and routine practice pragmatism for exercise as 
an antidepressant treatment, preferred intensity exercise appears to be “fitting well” into 
routine practice.  
In sum, we thank Drs Legrand and Neff for raising these interesting points. In many ways, we 
share similar views, common research findings, and the desire to utilize exercise as a 
treatment for people with depression. We hope that the clinical evidence that has 
demonstrated the antidepressant impact of exercise in robust RCTs (20, 22)  and meta-
analyses (14, 23, 24) can soon translate into broad changes in routine practice within emerging 
stepped-care collaborative approaches to treatment. We maintain that pragmatic RCTs will be 
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